Brentuximab vedotin for the treatment of Hodgkin’s and non-Hodgkin’s lymphoma

Bibliography

• GPCanellos, JRAnderson, KJPropert, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327(21):1478-84
   PubMed Web of Science ®Google Scholar
• GPCanellos, DNiedzwiecki. Long-term follow-up of Hodgkin’s disease trial. N Engl J Med 2002;346(18):1417-18
   PubMed Web of Science ®Google Scholar
• AEngert, APlutschow, HTEich, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010;363(7):640-52
   PubMed Web of Science ®Google Scholar
• DCLinch, DWinfield, AHGoldstone, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: Results of a BNLI randomised trial. Lancet 1993;341(8852):1051-4
   PubMed Web of Science ®Google Scholar
• NSMajhail, DJWeisdorf, TEDefor, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2006;12(10):1065-72
   PubMed Web of Science ®Google Scholar
• AJosting, CRudolph, MMapara, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16(1):116-23
   PubMed Web of Science ®Google Scholar
• ASGerrie, MMPower, JDShepherd, et al. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Ann Oncol 2014;25(11):2218-23
   Google Scholar
• NLBartlett, AYounes, MHCarabasi, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111(4):1848-54
   PubMed Web of Science ®Google Scholar
• AYounes, AKGopal, SESmith, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30(18):2183-9
   PubMed Web of Science ®Google Scholar
• CBossard, MPDobay, MParrens, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: High correlation with mRNA levels. Blood 2014;124(19):2983-6
   PubMed Web of Science ®Google Scholar
• JVose, JArmitage, DWeisenburger; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 2008;26(25):4124-30
   PubMed Web of Science ®Google Scholar
• AJMoskowitz, PAHamlinJr, MAPerales, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31(4):456-60
   PubMed Web of Science ®Google Scholar
• RLittle, REWittes, DLLongo, WHWilson. Vinblastine for recurrent Hodgkin’s disease following autologous bone marrow transplant. J Clin Oncol 1998;16(2):584-8
   PubMed Web of Science ®Google Scholar
• ASantoro, HBredenfeld, LDevizzi, et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: Results of a multicenter phase II study. J Clin Oncol 2000;18(13):2615-19
   PubMed Web of Science ®Google Scholar
• AYounes, ASureda, DBen-Yehuda, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: Results of a phase II study. J Clin Oncol 2012;30(18):2197-203
   PubMed Web of Science ®Google Scholar
• MHKirschbaum, BHGoldman, JMZain, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest oncology group study S0517. Leuk Lymphoma 2012;53(2):259-62
   PubMed Web of Science ®Google Scholar
• YOki, DBuglio, MFanale, et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 2013;19(24):6882-90
   PubMed Web of Science ®Google Scholar
• TAFehniger, SLarson, KTrinkaus, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118(19):5119-25
   PubMed Web of Science ®Google Scholar
• SMAnsell, AMLesokhin, IBorrello, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372(4):311-19
   PubMed Web of Science ®Google Scholar
• CHMoskowitz, VRibrag, JMMichot, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a phase 1b study (KEYNOTE-013). Blood 2014;124:21
   Google Scholar
• SODoronina, BEToki, MYTorgov, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21(7):778-84
   PubMed Web of Science ®Google Scholar
• AFWahl, KKlussman, JDThompson, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res 2002;62(13):3736-42
   PubMed Web of Science ®Google Scholar
• JAFrancisco, CGCerveny, DLMeyer, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102(4):1458-65
   PubMed Web of Science ®Google Scholar
• KJHamblett, PDSenter, DFChace, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody-drug conjugate. Clin Cancer Res 2004;10(20):7063-70
   PubMed Web of Science ®Google Scholar
• RJSanderson, MAHering, SFJames, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005;11(2 Pt 1):843-52
   PubMed Web of Science ®Google Scholar
• MSSutherland, RJSanderson, KAGordon, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281(15):10540-7
   PubMed Web of Science ®Google Scholar
• NMOkeley, JBMiyamoto, XZhang, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16(3):888-97
   PubMed Web of Science ®Google Scholar
• PMuller, KMartin, STheurich, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res 2014;2(8):741-55
   Google Scholar
• EOflazoglu, KMKissler, ELSievers, et al. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008;142(1):69-73
   PubMed Web of Science ®Google Scholar
• AYounes, NLBartlett, JPLeonard, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363(19):1812-21
   PubMed Web of Science ®Google Scholar
• STheurich, JMalcher, KWennhold, et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2013;31(5):e59-63
   PubMed Web of Science ®Google Scholar
• MAFanale, AForero-Torres, JDRosenblatt, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18(1):248-55
   PubMed Web of Science ®Google Scholar
• THHan, AKGopal, RRamchandren, et al. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol 2013;53(8):866-77
   PubMed Web of Science ®Google Scholar
• AForero-Torres, JPLeonard, AYounes, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146(2):171-9
   PubMed Web of Science ®Google Scholar
• AForero-Torres, MFanale, RAdvani, et al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: Analysis of two phase I studies. Oncologist 2012;17(8):1073-80
   PubMedGoogle Scholar
• PLZinzani, SViviani, AAnastasia, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: The Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 2013;98(8):1232-6
   PubMed Web of Science ®Google Scholar
• ARothe, SSasse, HGoergen, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: The German Hodgkin Study Group experience. Blood 2012;120(7):1470-2
   PubMed Web of Science ®Google Scholar
• TIllidge, RBouabdallah, RChen, et al. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma 2015;1-8. [Epub ahead of print]
   Google Scholar
• RChen, JMPalmer, SHThomas, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012;119(26):6379-81
   PubMed Web of Science ®Google Scholar
• AKGopal, RRamchandren, OAO’Connor, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012;120(3):560-8
   PubMed Web of Science ®Google Scholar
• BPro, RAdvani, PBrice, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol 2012;30(18):2190-6
   PubMed Web of Science ®Google Scholar
• BPro, RAdvani, PBrice, et al. Four-year survival data from an ongoing pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2014;124:21
   Google Scholar
• SMHorwitz, RHAdvani, NLBartlett, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123(20):3095-100
   PubMed Web of Science ®Google Scholar
• JAparicio, ASegura, SGarcera, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol 1999;10(5):593-5
   PubMed Web of Science ®Google Scholar
• CHMoskowitz, SDNimer, ADZelenetz, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 2001;97(3):616-23
   PubMed Web of Science ®Google Scholar
• NLBartlett, DNiedzwiecki, JLJohnson, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007;18(6):1071-9
   PubMed Web of Science ®Google Scholar
• RWChen, JPalmer, PMartin, et al. Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. Blood 2014;124:21
   Google Scholar
• ASLaCasce, RGBociek, JMatous, et al. Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy. Blood 2014;124:21
   Google Scholar
• CHMoskowitz, ANademanee, TMasszi, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• AYounes, JMConnors, SIPark, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: A phase 1, open-label, dose-escalation study. Lancet Oncol 2013;14(13):1348-56
   PubMed Web of Science ®Google Scholar
• JMConnors, SAnsell, SIPark, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed advanced stage Hodgkin lymphoma: long term outcomes. Blood 2014;124:21
   Google Scholar
• SIPark, KLRichards, OOlajide, et al. A phase 2 trial of induction chemotherapy with ABVD followed by brentuximab vedotin consolidation in patients with previously untreated non-bulky stage I or II Hodgkin lymphoma. Blood 2014;124:21
   Google Scholar
• AKumar, JYahalom, HScoder, et al. Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma. Blood 2014;124:21
   Google Scholar
• AForero-Torres, BHolkova, JPSharman, et al. Brentuximab vedotin monotherapy and in combination with dacarbazine in frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: Interim results of a phase 2 study. Blood 2014;124:21
   Google Scholar
• MAFanale, SMHorwitz, AForero-Torres, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: Results of a phase I study. J Clin Oncol 2014;32(28):3137-43
   PubMed Web of Science ®Google Scholar
• AForero-Torres, NLBartlett, RBBerryman, et al. Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Leuk Lymphoma 2014. [Epub ahead of print]
   Google Scholar
• MDGandhi, AMEvens, TSFenske, et al. Pancreatitis in patients treated with brentuximab vedotin: A previously unrecognized serious adverse event. Blood 2014;123(18):2895-7
   PubMed Web of Science ®Google Scholar
• KRCarson, SDNewsome, EJKim, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the southern network on adverse reactions (SONAR) project. Cancer 2014;120(16):2464-71
   PubMed Web of Science ®Google Scholar
• MAFanale, SMHorwitz, AForero-Torres, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: Results of a phase I study. J Clin Oncol 2014;32(28):3137-43
   PubMed Web of Science ®Google Scholar
• RAde Claro, KMcGinn, VKwitkowski, et al. U.S. food and drug administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18(21):5845-9
   PubMed Web of Science ®Google Scholar
• Patient assistance and reimbursement support [Internet]. 2014. Available from: http://www.seagensecure.com/home/patient-assistance/patient-assistance.html
   Google Scholar
• SHu, ZYXu-Monette, ABalasubramanyam, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the international DLBCL rituximab-CHOP consortium program study. Blood 2013;121(14):2715-24
   PubMed Web of Science ®Google Scholar
• GWSlack, CSteidl, LHSehn, RDGascoyne. CD30 expression in de novo diffuse large B-cell lymphoma: A population-based study from British Columbia. Br J Haematol 2014;167(5):608-17
   PubMed Web of Science ®Google Scholar
• EDJacobsen, JPSharman, YOki, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015;125(9):1394-402
   PubMed Web of Science ®Google Scholar
• CAYasenchak, CMFarber, LEBudde, et al. Brentuximab vedotin in combination with RCHOP as frontline therapy in patients with diffuse large B-cell lymphoma: interim results from a phase 2 study. Blood 2014;124:21
   Google Scholar
• RChen, JHou, ENewman, et al. Downregulation of CD30, resistance to MMAE, and upregulation of MDR1 are all associated with resistance to brentuximab vedotin. Blood 2014;124:21
   Google Scholar
• SLLocatelli, STartari, LCastagna, et al. The PI3K-delta inhibitor TGR-1202 in combination with brentuximab vedotin (SGN-35) synergistically inhibits tubulin polymerization and exerts potent antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. Blood 2014;124:21
   Google Scholar